Immune Checkpoint Inhibitor Clinical Trials

11 recruiting

Immune Checkpoint Inhibitor Trials at a Glance

35 actively recruiting trials for immune checkpoint inhibitor are listed on ClinicalTrialsFinder across 6 cities in 9 countries. The largest study group is Phase 2 with 9 trials, with the heaviest enrollment activity in Beijing, Montpellier, and Beijing. Lead sponsors running immune checkpoint inhibitor studies include Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, and Second Xiangya Hospital of Central South University.

Browse immune checkpoint inhibitor trials by phase

Treatments under study

About Immune Checkpoint Inhibitor Clinical Trials

Looking for clinical trials for Immune Checkpoint Inhibitor? There are currently 11 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Immune Checkpoint Inhibitor trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Immune Checkpoint Inhibitor clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 35 trials

Recruiting
Phase 2

Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors

Lung CancerRadiotherapyImmune Checkpoint Inhibitor+1 more
Tianjin Medical University Cancer Institute and Hospital30 enrolled3 locationsNCT07058948
Recruiting

Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors

Lung CancerVenous ThromboembolismArterial Thromboembolism+1 more
Beijing Chao Yang Hospital2,400 enrolled5 locationsNCT06950697
Recruiting
Phase 3

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

Urinary Bladder NeoplasmsImmune Checkpoint InhibitorsMethotrexate+4 more
AstraZeneca150 enrolled59 locationsNCT06960577
Recruiting
Phase 2

Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction

Stomach NeoplasmsImmune Checkpoint Inhibitors
Xijing Hospital116 enrolled5 locationsNCT06576921
Recruiting

A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy

Immune Checkpoint InhibitorsArthritisPolymyalgia Rheumatica
M.D. Anderson Cancer Center20 enrolled1 locationNCT06647134
Recruiting
Not Applicable

Understanding of Rare Inflammatory Arthritis in Comparison to Classical Inflammatory Arthritis : Tissular Observations and Immune Infiltrate Characterization : the UTOPIC Project

Inflammatory ArthritisRare Auto-immune DiseasesImmune Checkpoint Inhibitor Related Inflamamtory Arthritis
University Hospital, Brest100 enrolled2 locationsNCT07302074
Recruiting

Observational Cohort Study of Chronic Viral Infection in the Central Nervous System

Immune Checkpoint InhibitorsProgressive Multifocal Leukoencephalopathy
Peking Union Medical College Hospital66 enrolled1 locationNCT07512518
Recruiting
Phase 3

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

ChemotherapyRadiotherapyImmune Checkpoint Inhibitor+1 more
Sun Yat-sen University380 enrolled3 locationsNCT05941741
Recruiting
Phase 2

Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial

Immune Checkpoint Inhibitor-Related Colitis
Shilpa Grover, MD, MPH80 enrolled2 locationsNCT06841705
Recruiting
Phase 2

JAK Inhibitors for Solid Malignant Tumor Patients With Immune Checkpoint Inhibitors-related Dermatitis: A Open-lable, Single Arm, Phase IIa Trial

Immune Checkpoint Inhibitors (ICI)-Related Dermatitis
Shixiu Wu35 enrolled1 locationNCT06715982
Recruiting

FDG-PET as an Imaging Modality to Diagnose and Risk Stratify Subclinical, Imaging Negative Ici-Myocarditis

Hematologic MalignancyMyocarditisSubclinical Immune Checkpoint Inhibitor-Induced Myocarditis+4 more
Mayo Clinic30 enrolled1 locationNCT06566209
Recruiting
Phase 3

Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC

Radiotherapy, AdjuvantHepatocellular Carcinoma (HCC)Immune Checkpoint Inhibitor+2 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences286 enrolled1 locationNCT07186621
Recruiting
Phase 2

A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy

Renal Cell CarcinomaRadiotherapyImmune Checkpoint Inhibitor
Jinling Hospital, China35 enrolled1 locationNCT06255223
Recruiting

The Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study

Unresectable Hepatocellular CarcinomaPsychological DistressHCC - Hepatocellular Carcinoma+2 more
Guilin Medical University, China700 enrolled5 locationsNCT07141056
Recruiting
Phase 1

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

MelanomaNeoplasmsNeoplasms by Site+7 more
Yana Najjar50 enrolled2 locationsNCT04572451
Recruiting

Cardiac Magnetic Resonance Monitoring of Immune Checkpoint Inhibitor-related Cardiotoxicity

Immune Checkpoint Inhibitors, Cardiotoxicity
West China Second University Hospital22 enrolled1 locationNCT06132984
Recruiting
Not Applicable

Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLC

Lung CancerRadiotherapyImmune Checkpoint Inhibitor
Xinqiao Hospital of Chongqing40 enrolled2 locationsNCT05754203
Recruiting
Not Applicable

Liver Cancer and Immunotherapy in the Liquid Biopsy Era

Hepatocellular CarcinomaImmune Checkpoint InhibitorLiquid Biopsy+2 more
University Hospital, Montpellier60 enrolled1 locationNCT05810402
Recruiting
Not Applicable

Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients Undergoing Immune CheckPoint Inhibitors (ICPI) Treatment

ImmunotherapyImmune Checkpoint InhibitorsImmune-related Adverse Event+1 more
Centre Hospitalier Universitaire, Amiens150 enrolled1 locationNCT05813418
Recruiting

The Associations of Sleep Disturbance With Therapy Efficacy and Prognosis of Lung Cancer

Lung CancerSleep DisturbanceCancer, Treatment-Related+1 more
Second Xiangya Hospital of Central South University1,270 enrolled1 locationNCT06975384